ongoing

Recurrence is a common problem after catheter ablation for atrial fibrillation (AF), affecting at least one out of three patients. Inflammation due to the procedure may contribute to pulmonary vein reconnection and, thus, failure of catheter ablation.

The IMPROVE-PVI pilot study will assess whether a randomized, placebo-controlled trial investigating a 10-day treatment with colchicine, a potent anti-inflammatory drug, to improve patient relevant outcomes after catheter ablation for atrial fibrillation is feasible.

Study Type

Interventional - Drug

Study Design

Pilot RCT

NO. of Countries

1

NO. of Participants

300

Study Period

2020-2021

Sponsor

PHRI

None

Internal funding (Connolly, Healey) 2. PI has applied for HHS New Investigator Fund 3. Other possibilities for funding are being investigated (e.g. HAHSO)

Back To Top